{"filing":{"accession_number":"0001570562-26-000079","cik":"0001570562","ticker":"EOLS","company_name":"Evolus, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"eols-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/eols-20260707.htm"},"events":[{"id":16630,"run_id":14862,"accession_number":"0001570562-26-000079","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.9,"summary":"Evolus entered into an exclusive License, Supply and Distribution Agreement with IBSA on July 7, 2026, granting exclusive rights to develop, commercialize, and distribute Profhilo® in the United States. The 15-year initial term agreement with renewal options expands the company's injectable portfolio into the skin-quality segment and includes minimum purchase requirements structured with a transfer-price model designed to support gross margins consistent with the company's long-term financial framework.","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14787,"accession_number":"0001570562-26-000079","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Evolus entered into an exclusive License, Supply and Distribution Agreement with IBSA on July 7, 2026, granting exclusive rights to develop, commercialize, and distribute Profhilo® in the United States. This is a material strategic transaction that expands the company's injectable portfolio into the skin-quality segment, a \"fastest growing and underpenetrated\" market. The agreement provides 15-year initial term rights with renewal options and includes minimum purchase requirements, representing a significant commercial commitment that would affect a reasonable investor's assessment of the company's growth strategy and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T13:04:42.537526+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14788,"accession_number":"0001570562-26-000079","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Evolus announced execution of an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo® in the United States. This represents a material strategic transaction that expands the company's injectable portfolio into a new product category (skin quality) and market segment. The agreement involves development responsibilities and commercialization rights, structured with a transfer-price model designed to support gross margins consistent with the company's long-term financial framework, indicating a significant commercial arrangement that materially affects the company's business strategy and growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T13:04:42.537526+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14787,"accession_number":"0001570562-26-000079","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Evolus entered into an exclusive License, Supply and Distribution Agreement with IBSA on July 7, 2026, granting exclusive rights to develop, commercialize, and distribute Profhilo® in the United States. This is a material strategic transaction that expands the company's injectable portfolio into the skin-quality segment, a \"fastest growing and underpenetrated\" market. The agreement provides 15-year initial term rights with renewal options and includes minimum purchase requirements, representing a significant commercial commitment that would affect a reasonable investor's assessment of the company's growth strategy and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T13:04:42.537526+00:00","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-07-08"},{"id":14788,"accession_number":"0001570562-26-000079","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Evolus announced execution of an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo® in the United States. This represents a material strategic transaction that expands the company's injectable portfolio into a new product category (skin quality) and market segment. The agreement involves development responsibilities and commercialization rights, structured with a transfer-price model designed to support gross margins consistent with the company's long-term financial framework, indicating a significant commercial arrangement that materially affects the company's business strategy and growth prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T13:04:42.537526+00:00","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-07-08"}]}